molecular imaging

The financing follows a $5.15 million Series A round completed in 2015 and will go toward development and commercialization of Ultivue's InSituPlex technology. 

Researchers at Tufts and their collaborators recently demonstrated that the approach, which uses multiphoton microscopy, can distinguish between normal and cancerous skin.